Chester County News and Community Website
WILMINGTON, DE — New data from the BaxHTN Phase III trial indicate that baxdrostat, an investigational aldosterone synthase inhibitor, achieved significant reductions in systolic blood pressure among patients with uncontrolled …
Phase III Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Hard-to-Treat Hypertension Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced new data published in JACC: Clinical Electrophysiology demonstrating the potential of its atrioventricular interval modulation (AVIM) therapy to reduce …
Orchestra BioMed Publishes Data Supporting Blood Pressure Therapy in Hypertensive Pacemaker Patients Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More
WEST CONSHOHOCKEN, PA — PRM Pharma, LLC has announced the availability of HEMICLOR® (12.5 mg chlorthalidone tablets), the first FDA-approved low-dose formulation of chlorthalidone for the treatment of hypertension in …
PRM Pharma Launches HEMICLOR, First FDA-Approved Low-Dose Chlorthalidone Tablet Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More WEST CONSHOHOCKEN, PA — The U.S. Food and Drug Administration (FDA) has approved HemiClor, a 12.5 mg chlorthalidone tablet developed by PRM Pharma, LLC, for the treatment of hypertension in …
FDA Approves Low-Dose Hypertension Treatment HemiClor Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More
RADNOR, PA — Idorsia Pharmaceuticals U.S. Inc. has announced the availability of TRYVIO™ (aprocitentan) in the United States for adults suffering from hypertension. This new medication is intended to be used …
New Hypertension Treatment TRYVIO Now Available in the U.S. Read More